Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.
about
Current Status of Hepatic Arterial Infusion Chemotherapy2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaTargeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review.Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma.Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
P2860
Q26775437-D0CB54DB-37C9-4266-A099-1EC7E0D21C32Q28392783-04F7AFA1-D24C-40F0-8DCD-5AA9F06FC178Q28394414-945FC485-19DD-4B5A-8B76-DE0F6F0775C2Q35273600-3402F1E5-F979-44EA-8599-F5E92EFE085DQ36035607-4907C74E-2AF6-4AA2-8582-54D082E79AE4Q36210228-218D2B91-F05A-4650-831C-4FA16200BAC7Q37252306-051EF419-F550-44D8-B1AA-DE433C9218A4Q38264330-73CA8EF0-12EB-45C0-85B6-B964CB08BDEFQ38720054-64B77229-7FF7-4CAC-AFB6-6C91B35E2A66Q39112472-AB5B2954-2EED-4EFA-A70F-187802CE2568Q40461237-94B1B7C3-A5B8-4641-A84D-1C7DF643712CQ40798040-EA89B5B5-30F1-4ECA-B726-D9199E0D8373Q40955279-E32F1476-33B1-49D0-AA3A-659A7A091845Q58806056-A0A76602-FCC6-4803-8A24-99C57D066572
P2860
Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@ast
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@en
type
label
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@ast
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@en
prefLabel
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@ast
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@en
P2093
P2860
P356
P1433
P1476
Feasibility and efficacy of he ...... lar carcinoma after sorafenib.
@en
P2093
Eishiro Mizukoshi
Hajime Sunagozaka
Hidetoshi Nakagawa
Kuniaki Arai
Masaaki Kitahara
Masao Honda
Shuichi Kaneko
Takashi Kagaya
Takeshi Terashima
Tatsuya Yamashita
P2860
P304
P356
10.1111/HEPR.12266
P577
2014-01-08T00:00:00Z